This HTML5 document contains 164 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00878/identifier/chebi/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/AHFS/
n17http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/mixture/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00878/identifier/wikipedia/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00878/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00878/identifier/kegg-compound/
n27http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00878/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/patent/
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00878/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n16http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n22http://www.drugs.com/cdi/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00878/identifier/national-drug-code-directory/
n28http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00878
rdf:type
n3:Drug
n3:description
A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque. [PubChem]
n3:dosage
n13:271B55FF-363D-11E5-9242-09173F13E4C5 n13:271B55FE-363D-11E5-9242-09173F13E4C5 n13:271B5600-363D-11E5-9242-09173F13E4C5 n13:271B5601-363D-11E5-9242-09173F13E4C5 n13:271B5602-363D-11E5-9242-09173F13E4C5 n13:271B5603-363D-11E5-9242-09173F13E4C5 n13:271B55FB-363D-11E5-9242-09173F13E4C5 n13:271B55FC-363D-11E5-9242-09173F13E4C5 n13:271B55FD-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# McBain AJ, Bartolo RG, Catrenich CE, Charbonneau D, Ledder RG, Gilbert P: Effects of a chlorhexidine gluconate-containing mouthwash on the vitality and antimicrobial susceptibility of in vitro oral bacterial ecosystems. Appl Environ Microbiol. 2003 Aug;69(8):4770-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12902270
n3:group
approved
n3:indication
For reduction of pocket depth in patients with adult periodontitis, used as an adjunct to scaling and root planing procedures. Also for prevention of dental caries, oropharyngeal decontamination in critically ill patients, hand hygiene in health-care personnel, general skin cleanser, and catheter site preparation and care.
n3:manufacturer
n4:271B55E9-363D-11E5-9242-09173F13E4C5 n4:271B55EA-363D-11E5-9242-09173F13E4C5 n4:271B55E7-363D-11E5-9242-09173F13E4C5 n4:271B55E8-363D-11E5-9242-09173F13E4C5 n4:271B55ED-363D-11E5-9242-09173F13E4C5 n4:271B55EB-363D-11E5-9242-09173F13E4C5 n4:271B55EC-363D-11E5-9242-09173F13E4C5 n4:271B55E1-363D-11E5-9242-09173F13E4C5 n4:271B55E2-363D-11E5-9242-09173F13E4C5 n4:271B55DF-363D-11E5-9242-09173F13E4C5 n4:271B55E0-363D-11E5-9242-09173F13E4C5 n4:271B55E5-363D-11E5-9242-09173F13E4C5 n4:271B55E6-363D-11E5-9242-09173F13E4C5 n4:271B55E3-363D-11E5-9242-09173F13E4C5 n4:271B55E4-363D-11E5-9242-09173F13E4C5 n4:271B55D9-363D-11E5-9242-09173F13E4C5 n4:271B55DA-363D-11E5-9242-09173F13E4C5 n4:271B55D8-363D-11E5-9242-09173F13E4C5 n4:271B55DD-363D-11E5-9242-09173F13E4C5 n4:271B55DE-363D-11E5-9242-09173F13E4C5 n4:271B55DB-363D-11E5-9242-09173F13E4C5 n4:271B55DC-363D-11E5-9242-09173F13E4C5
owl:sameAs
n12:DB00878 n27:DB00878
dcterms:title
Chlorhexidine
adms:identifier
n8:PA164776863 n20:C06902 n23:D07668 n24:DB00878 n25:0116-2001-16 n26:3614 n29:Chlorhexidine
n3:mechanismOfAction
Chlorhexidine's antimicrobial effects are associated with the attractions between chlorhexidine (cation) and negatively charged bacterial cells. After chlorhexidine is absorpted onto the organism's cell wall, it disrupts the integrity of the cell membrane and causes the leakage of intracellular components of the organisms.
n3:packager
n4:271B55B5-363D-11E5-9242-09173F13E4C5 n4:271B55B6-363D-11E5-9242-09173F13E4C5 n4:271B55B3-363D-11E5-9242-09173F13E4C5 n4:271B55B4-363D-11E5-9242-09173F13E4C5 n4:271B55CD-363D-11E5-9242-09173F13E4C5 n4:271B55CE-363D-11E5-9242-09173F13E4C5 n4:271B55CB-363D-11E5-9242-09173F13E4C5 n4:271B55CC-363D-11E5-9242-09173F13E4C5 n4:271B55C9-363D-11E5-9242-09173F13E4C5 n4:271B55CA-363D-11E5-9242-09173F13E4C5 n4:271B55C7-363D-11E5-9242-09173F13E4C5 n4:271B55C8-363D-11E5-9242-09173F13E4C5 n4:271B55D5-363D-11E5-9242-09173F13E4C5 n4:271B55D6-363D-11E5-9242-09173F13E4C5 n4:271B55D3-363D-11E5-9242-09173F13E4C5 n4:271B55D4-363D-11E5-9242-09173F13E4C5 n4:271B55D1-363D-11E5-9242-09173F13E4C5 n4:271B55D2-363D-11E5-9242-09173F13E4C5 n4:271B55CF-363D-11E5-9242-09173F13E4C5 n4:271B55D0-363D-11E5-9242-09173F13E4C5 n4:271B55BD-363D-11E5-9242-09173F13E4C5 n4:271B55BE-363D-11E5-9242-09173F13E4C5 n4:271B55BB-363D-11E5-9242-09173F13E4C5 n4:271B55BC-363D-11E5-9242-09173F13E4C5 n4:271B55B9-363D-11E5-9242-09173F13E4C5 n4:271B55BA-363D-11E5-9242-09173F13E4C5 n4:271B55B7-363D-11E5-9242-09173F13E4C5 n4:271B55B8-363D-11E5-9242-09173F13E4C5 n4:271B55C5-363D-11E5-9242-09173F13E4C5 n4:271B55C6-363D-11E5-9242-09173F13E4C5 n4:271B55C3-363D-11E5-9242-09173F13E4C5 n4:271B55C4-363D-11E5-9242-09173F13E4C5 n4:271B55C1-363D-11E5-9242-09173F13E4C5 n4:271B55C2-363D-11E5-9242-09173F13E4C5 n4:271B55BF-363D-11E5-9242-09173F13E4C5 n4:271B55C0-363D-11E5-9242-09173F13E4C5 n4:271B55D7-363D-11E5-9242-09173F13E4C5
n3:patent
n15:7427574 n15:7595021
n3:routeOfElimination
Excretion of chlorhexidine gluconate occurred primarily through the feces (~90%). Less than 1% of the chlorhexidine gluconate ingested by these subjects was excreted in the urine.
n3:synonym
Chlorhexidine Cloresidina N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide Chlorhexidinum Chlorhexidin 1,1'-Hexamethylene bis(5-(P-chlorophenyl)biguanide) Clorhexidina
n3:toxicity
LD<sub>50</sub>= 2g/kg (human, oral); LD<sub>50</sub>= 3 g/kg (rat, oral); LD<sub>50</sub>= 2.5 g/kg (mice, oral); LD<sub>50</sub>= 21 mg/kg (male rat, IV); LD<sub>50</sub>= 23 mg/kg (female rat, IV); LD<sub>50</sub>= 25 mg/kg (male mice, IV); LD<sub>50</sub>= 24 mg/kg (female mice, IV); LD<sub>50</sub>= 1g/kg (rat, subcutaneous); LD<sub>50</sub>= 637 mg/kg (male mice, subcutaneous); LD<sub>50</sub>= 632 mg/kg (female mice, subcutaneous)
n9:hasAHFSCode
n18:84-04-92 n18:34-00-00 n18:52-04-92
n3:mixture
n14:271B55AE-363D-11E5-9242-09173F13E4C5 n14:271B55AF-363D-11E5-9242-09173F13E4C5 n14:271B55AD-363D-11E5-9242-09173F13E4C5 n14:271B55B2-363D-11E5-9242-09173F13E4C5 n14:271B55B0-363D-11E5-9242-09173F13E4C5 n14:271B55B1-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
87%
n3:salt
n3:synthesisReference
Rose, F.L. and Swain, G.; US. Patent 2,684,924; July 27, 1954; assigned to Imperial Chemical Industries, Ltd.
n16:hasConcept
n17:M0004138
foaf:page
n22:chlorhexidine-liquid.html n28:chlorhexidine.htm
n3:IUPAC-Name
n6:271B5608-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B560E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B560D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B560A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B560B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B560C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B561D-363D-11E5-9242-09173F13E4C5 n6:271B5606-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B561F-363D-11E5-9242-09173F13E4C5 n6:271B5607-363D-11E5-9242-09173F13E4C5 n6:271B5604-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B5605-363D-11E5-9242-09173F13E4C5
n3:pKa
n6:271B5620-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:S01AX09 n10:R02AA05 n10:D09AA12 n10:S03AA04 n10:S02AA09 n10:B05CA02 n10:D08AC02 n10:A01AB03
n3:H-Bond-Acceptor-Count
n6:271B5614-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B5615-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B560F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B5610-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B5612-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B5611-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B5613-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorption of chlorhexidine from the gastrointestinal tract is very poor. Additionally, an in vivo study in 18 adult patients found no detectable plasma or urine chlorhexidine concentrations following insertion of four periodontal implants under clinical conditions.
n3:affectedOrganism
Bacteria
n3:casRegistryNumber
55-56-1
n3:category
n3:containedIn
n5:271B55F1-363D-11E5-9242-09173F13E4C5 n5:271B55F6-363D-11E5-9242-09173F13E4C5 n5:271B55F7-363D-11E5-9242-09173F13E4C5 n5:271B55FA-363D-11E5-9242-09173F13E4C5 n5:271B55F8-363D-11E5-9242-09173F13E4C5 n5:271B55F9-363D-11E5-9242-09173F13E4C5 n5:271B55EE-363D-11E5-9242-09173F13E4C5 n5:271B55EF-363D-11E5-9242-09173F13E4C5 n5:271B55F4-363D-11E5-9242-09173F13E4C5 n5:271B55F5-363D-11E5-9242-09173F13E4C5 n5:271B55F2-363D-11E5-9242-09173F13E4C5 n5:271B55F3-363D-11E5-9242-09173F13E4C5 n5:271B55F0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B5619-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B561B-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B561C-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B561E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B5618-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B5617-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B561A-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B5609-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B5616-363D-11E5-9242-09173F13E4C5